nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at
NCT01930045,"ClinicalTrials.gov processed this data on August 01, 2018",2013-08-23,2014-10-29,NA,2017-02-14,2013-08-23,2013-08-28,Estimate,2014-10-29,2014-11-03,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,October 2013,NA,2013-10-31,February 2017,2017-02-28,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,NA,Interventional,NA,,A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295),A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen,Completed,NA,Phase 1,18,Actual,Merck Sharp & Dohme Corp.,,6,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T03:03:00Z,2018-08-02T03:03:00Z
NCT01792570,"ClinicalTrials.gov processed this data on August 01, 2018",2013-02-07,NA,NA,2016-03-29,2013-02-14,2013-02-15,Estimate,NA,NA,NA,NA,NA,NA,2016-03-29,2016-03-30,Estimate,September 2014,NA,2014-09-30,March 2016,2016-03-31,October 2017,Anticipated,2017-10-31,September 2017,Anticipated,2017-09-30,NA,Interventional,NA,,DRV/r + RPV QD: Efficacy and Toxicity Reduction,Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.,Unknown status,Recruiting,Phase 3,132,Anticipated,ASST Fatebenefratelli Sacco,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,NA,2018-08-02T03:47:01Z,2018-08-02T03:47:01Z
NCT01717287,"ClinicalTrials.gov processed this data on August 01, 2018",2012-10-26,2014-06-30,NA,2017-02-14,2012-10-26,2012-10-30,Estimate,2014-06-30,2014-07-29,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,November 2012,NA,2012-11-30,February 2017,2017-02-28,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,NA,Interventional,NA,,"A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)","A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination With Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and Antiretroviral Activity in HIV-1 Infected Russian Children and Adolescents",Completed,NA,Phase 2,32,Actual,Merck Sharp & Dohme Corp.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T04:15:31Z,2018-08-02T04:15:31Z
NCT01622673,"ClinicalTrials.gov processed this data on August 01, 2018",2012-06-15,2013-07-11,NA,2017-02-14,2012-06-15,2012-06-19,Estimate,2013-07-11,2013-09-17,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,June 2012,NA,2012-06-30,February 2017,2017-02-28,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,NA,Interventional,NA,,A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247),A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen,Completed,NA,Phase 1,27,Actual,Merck Sharp & Dohme Corp.,,6,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T04:48:10Z,2018-08-02T04:48:10Z
NCT01340950,"ClinicalTrials.gov processed this data on August 01, 2018",2011-04-21,NA,NA,2016-03-31,2011-04-22,2011-04-25,Estimate,NA,NA,NA,NA,NA,NA,2016-03-31,2016-04-04,Estimate,July 2010,NA,2010-07-31,March 2016,2016-03-31,July 2015,Actual,2015-07-31,July 2014,Actual,2014-07-31,NA,Interventional,NA,,Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China,Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China,Completed,NA,Phase 4,250,Actual,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Data will be shared in conference presentations and peer-reviewed publications. Data will also be made available on approval of requests for appropriate use.,2018-08-02T06:37:38Z,2018-08-02T06:37:38Z
NCT01246401,"ClinicalTrials.gov processed this data on August 01, 2018",2010-11-22,2017-02-27,NA,2017-06-14,2010-11-22,2010-11-23,Estimate,2017-06-14,2017-07-17,Actual,NA,NA,NA,2017-06-14,2017-07-17,Actual,March 2011,NA,2011-03-31,June 2017,2017-06-30,July 2016,Actual,2016-07-31,March 2016,Actual,2016-03-31,NA,Interventional,NewHope,,Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations,Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations,Completed,NA,Phase 1/Phase 2,151,Actual,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,"Data has been shared with the National Institute on Drug Abuse as a site in the data harmonization project associated with Seek, Test, Treat and Retain for Criminal Justice Populations.",2018-08-02T07:35:50Z,2018-08-02T07:35:50Z
NCT01165203,"ClinicalTrials.gov processed this data on August 01, 2018",2010-07-15,2017-05-11,2013-04-11,2018-03-30,2010-07-15,2010-07-19,Estimate,2017-05-11,2017-06-07,Actual,2013-04-11,2013-04-18,Estimate,2018-03-30,2018-04-30,Actual,"September 30, 2010",Actual,2010-09-30,October 2017,2017-10-31,"May 14, 2013",Actual,2013-05-14,"July 6, 2012",Actual,2012-07-06,NA,Interventional,NA,,Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects,Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects,Completed,NA,Phase 2,123,Actual,GlaxoSmithKline,,2,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2018-08-02T08:12:15Z,2018-08-02T08:12:15Z
NCT01159223,"ClinicalTrials.gov processed this data on August 01, 2018",2010-06-04,NA,NA,2016-08-17,2010-07-08,2010-07-09,Estimate,NA,NA,NA,NA,NA,NA,2016-08-17,2016-08-18,Estimate,May 2011,NA,2011-05-31,August 2016,2016-08-31,June 2015,Actual,2015-06-30,December 2014,Actual,2014-12-31,NA,Interventional,NA,,Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA),A Multicenter Randomized Study to Compare the Efficacy and Safety of Lower Dose Atazanavir /Ritonavir (ATV/r 200/100 OD) Versus Standard Dose (ATV/r 300/100 mg OD) in Combination With 2NRTIs in Well Virology Suppressed HIV-infected Adults,Completed,NA,Phase 4,559,Actual,The HIV Netherlands Australia Thailand Research Collaboration,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,study protocol available at www.hivnat.org,2018-08-02T08:13:53Z,2018-08-02T08:13:53Z
NCT01147107,"ClinicalTrials.gov processed this data on August 01, 2018",2010-06-16,NA,NA,2017-03-06,2010-06-16,2010-06-22,Estimate,NA,NA,NA,NA,NA,NA,2017-03-06,2017-03-08,Actual,February 2014,NA,2014-02-28,March 2017,2017-03-31,June 2017,Anticipated,2017-06-30,December 2016,Actual,2016-12-31,NA,Interventional,NA,,Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection,Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-NaÃ¯ve HIV-infected Subjects Co-Infected With Hepatitis C,"Active, not recruiting",NA,Phase 4,80,Anticipated,University of Hawaii,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,IPD will be shared with other researchers upon request following the publication of the data. Researchers will contact the PI.,2018-08-02T08:17:15Z,2018-08-02T08:17:15Z
NCT01000818,"ClinicalTrials.gov processed this data on August 01, 2018",2009-10-22,2010-03-10,NA,2017-02-14,2009-10-22,2009-10-23,Estimate,2010-05-03,2010-05-28,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,June 2008,NA,2008-06-30,February 2017,2017-02-28,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,NA,Interventional,NA,,A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054),"An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen",Completed,NA,Phase 1,18,Actual,Merck Sharp & Dohme Corp.,,3,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T09:02:23Z,2018-08-02T09:02:23Z
NCT00959699,"ClinicalTrials.gov processed this data on August 01, 2018",2009-07-29,2013-05-08,NA,2017-03-09,2009-08-14,2009-08-17,Estimate,2013-07-26,2013-08-30,Estimate,NA,NA,NA,2017-03-09,2017-04-07,Actual,November 2009,NA,2009-11-30,March 2017,2017-03-31,October 2012,Actual,2012-10-31,May 2012,Actual,2012-05-31,NA,Interventional,NA,,"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411)",Completed,NA,Phase 2,99,Actual,Merck Sharp & Dohme Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T09:16:37Z,2018-08-02T09:16:37Z
NCT00829010,"ClinicalTrials.gov processed this data on August 01, 2018",2009-01-22,2012-05-08,NA,2017-10-23,2009-01-22,2009-01-26,Estimate,2012-05-31,2012-07-06,Estimate,NA,NA,NA,2017-10-23,2017-11-27,Actual,"February 17, 2009",NA,2009-02-17,October 2017,2017-10-31,"June 27, 2012",Actual,2012-06-27,"June 13, 2011",Actual,2011-06-13,NA,Interventional,NA,,"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","Primary and Booster Vaccination Course in Human Immunodeficiency Virus (HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK 1024850A.",Completed,NA,Phase 3,489,Actual,GlaxoSmithKline,"The study aimed to enrol 100 HIV+/+ subjects but succeeded to enrol 83 mainly due to decrease of vertical HIV transmission in South Africa. Some subjects, HIV+ at screening, tested negative at subsequent HIV testing, were reallocated in HIV+/-Group.",5,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2018-08-02T10:04:13Z,2018-08-02T10:04:13Z
NCT00764946,"ClinicalTrials.gov processed this data on August 01, 2018",2008-10-01,2012-02-13,NA,2017-02-14,2008-10-01,2008-10-02,Estimate,2012-03-16,2012-04-12,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,October 2008,NA,2008-10-31,February 2017,2017-02-28,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,NA,Interventional,NA,,A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055),"A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients",Completed,NA,Phase 3,209,Actual,Merck Sharp & Dohme Corp.,,1,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T10:29:19Z,2018-08-02T10:29:19Z
NCT00687544,"ClinicalTrials.gov processed this data on August 01, 2018",2008-05-27,2011-09-22,NA,2017-03-08,2008-05-29,2008-05-30,Estimate,2011-12-22,2012-01-30,Estimate,NA,NA,NA,2017-03-08,2017-04-06,Actual,December 2005,NA,2005-12-31,March 2017,2017-03-31,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,NA,Interventional,NA,,Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED),Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon,Terminated,NA,Phase 4,11,Actual,Merck Sharp & Dohme Corp.,The study was terminated early due to low enrollment. The primary and secondary outcomes were not evaluated. A formal safety analysis was not performed for the 11 participants enrolled in the study.,1,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T10:56:37Z,2018-08-02T10:56:37Z
NCT00623597,"ClinicalTrials.gov processed this data on August 01, 2018",2008-02-18,2015-12-10,NA,2016-02-04,2008-02-18,2008-02-26,Estimate,2015-12-10,2016-01-14,Estimate,NA,NA,NA,2016-02-04,2016-03-07,Estimate,June 2008,NA,2008-06-30,February 2016,2016-02-29,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,NA,Interventional,NA,The Safety Analysis Population (SAP) comprised all participants who received at least one dose of study medication. The SAP was used for all efficacy and safety analyses,A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.,A Phase I/II Study of InviraseÂ® Boosted With Ritonavir in HIV Infected Infants and Children 4 Months to Less Than 6 Years Old,Completed,NA,Phase 2,18,Actual,Hoffmann-La Roche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,NA,2018-08-02T11:19:43Z,2018-08-02T11:19:43Z
NCT00586339,"ClinicalTrials.gov processed this data on August 01, 2018",2007-12-21,2012-02-16,NA,2017-09-25,2007-12-21,2008-01-04,Estimate,2012-02-16,2012-03-22,Estimate,NA,NA,NA,2017-09-25,2017-10-26,Actual,"January 17, 2008",NA,2008-01-17,August 2016,2016-08-31,"July 18, 2011",Actual,2011-07-18,"July 18, 2011",Actual,2011-07-18,NA,Interventional,NA,,Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in HIV Infected Females,Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects,Completed,NA,Phase 2,150,Actual,GlaxoSmithKline,,3,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2018-08-02T11:33:45Z,2018-08-02T11:33:45Z
NCT00443729,"ClinicalTrials.gov processed this data on August 01, 2018",2007-03-02,2009-10-12,NA,2017-02-14,2007-03-05,2007-03-06,Estimate,2009-10-12,2009-11-19,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,May 2007,NA,2007-05-31,February 2017,2017-02-28,April 2009,Actual,2009-04-30,October 2008,Actual,2008-10-31,NA,Interventional,NA,,MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED),"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B",Terminated,NA,Phase 3,355,Actual,Merck Sharp & Dohme Corp.,Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRAâ„¢.,2,NA,"Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus
    lopinavir (+) ritonavir",FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T12:22:16Z,2018-08-02T12:22:16Z
NCT00443703,"ClinicalTrials.gov processed this data on August 01, 2018",2007-03-02,2009-10-16,NA,2017-02-14,2007-03-05,2007-03-06,Estimate,2009-10-16,2009-12-01,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,May 2007,NA,2007-05-31,February 2017,2017-02-28,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,NA,Interventional,NA,,MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED),"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A",Terminated,NA,Phase 3,352,Actual,Merck Sharp & Dohme Corp.,The reason for early termination: Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRAâ„¢.,2,NA,"primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus
    lopinavir (+) ritonavir",FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T12:22:17Z,2018-08-02T12:22:17Z
NCT00369941,"ClinicalTrials.gov processed this data on August 01, 2018",2006-08-29,2009-09-18,NA,2017-02-14,2006-08-29,2006-08-30,Estimate,2010-04-20,2010-05-11,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,August 2006,NA,2006-08-31,February 2017,2017-02-28,February 2012,Actual,2012-02-29,May 2009,Actual,2009-05-31,NA,Interventional,NA,,"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADAâ„¢",Completed,NA,Phase 3,566,Actual,Merck Sharp & Dohme Corp.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T12:48:28Z,2018-08-02T12:48:28Z
NCT00350272,"ClinicalTrials.gov processed this data on August 01, 2018",2006-07-06,2016-02-22,2014-01-20,2016-05-16,2006-07-07,2006-07-10,Estimate,2016-02-22,2016-03-22,Estimate,2014-01-20,2014-02-13,Estimate,2016-05-16,2016-06-17,Estimate,May 2006,NA,2006-05-31,May 2016,2016-05-31,April 2009,Actual,2009-04-30,August 2007,Actual,2007-08-31,NA,Interventional,NA,"The baseline analysis population was the safety population, defined as all randomized subjects who received at least one dose of study drug.","Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects","A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.",Completed,NA,Phase 2,76,Actual,Achillion Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Individual Participant Data is available to only this study's Principal Investigator upon request.,2018-08-02T12:54:31Z,2018-08-02T12:54:31Z
NCT00293254,"ClinicalTrials.gov processed this data on August 01, 2018",2006-02-15,2009-08-20,NA,2017-02-14,2006-02-15,2006-02-17,Estimate,2009-09-29,2009-09-30,Estimate,NA,NA,NA,2017-02-14,2017-03-21,Actual,February 2006,NA,2006-02-28,February 2017,2017-02-28,May 2011,Actual,2011-05-31,October 2007,Actual,2007-10-31,NA,Interventional,NA,,A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies",Completed,NA,Phase 3,351,Actual,Merck Sharp & Dohme Corp.,"Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 83 of 119 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.",2,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T13:11:57Z,2018-08-02T13:11:57Z
NCT00000143,"ClinicalTrials.gov processed this data on August 01, 2018",1999-09-23,2015-07-01,NA,2016-02-18,1999-09-23,1999-09-24,Estimate,2016-02-18,2016-03-14,Estimate,NA,NA,NA,2016-02-18,2016-03-14,Estimate,May 1997,NA,1997-05-31,July 2015,2015-07-31,June 2000,Actual,2000-06-30,June 2000,Actual,2000-06-30,NA,Interventional,GCCRT,,Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT),Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT),Completed,NA,Phase 3,61,Actual,Johns Hopkins Bloomberg School of Public Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,NA,2018-08-02T14:33:36Z,2018-08-02T14:33:36Z
NCT03575962,"ClinicalTrials.gov processed this data on August 01, 2018",2018-06-12,NA,NA,2018-07-23,2018-06-29,2018-07-03,Actual,NA,NA,NA,NA,NA,NA,2018-07-23,2018-07-24,Actual,"June 19, 2018",Actual,2018-06-19,July 2018,2018-07-31,"August 2, 2018",Anticipated,2018-08-02,"August 2, 2018",Anticipated,2018-08-02,NA,Interventional,NA,,A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254,"A Single Centre, 2-period, Randomized, Open-label Phase 1 Study to Assess the Relative Bioavailability of a Mesylate Salt Capsule of GSK3640254 Compared to a Hydrochloride Salt Capsule in Healthy Participants",Recruiting,NA,Phase 1,14,Anticipated,ViiV Healthcare,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2018-08-01T21:14:03Z,2018-08-01T21:14:03Z
NCT03564613,"ClinicalTrials.gov processed this data on August 01, 2018",2018-06-11,NA,NA,2018-07-11,2018-06-11,2018-06-21,Actual,NA,NA,NA,NA,NA,NA,2018-07-11,2018-07-13,Actual,"June 12, 2018",Actual,2018-06-12,July 2018,2018-07-31,"April 29, 2022",Anticipated,2022-04-29,"September 18, 2019",Anticipated,2019-09-18,NA,Observational,NA,,Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women,"DOLOMITE NEAT ID Network Study: A Prospective, Multi-site Observational Study to Define the Safety and Effectiveness of Dolutegravir Use in HIV Positive Pregnant Women","Active, not recruiting",NA,NA,250,Anticipated,ViiV Healthcare,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,Yes,IPD for this study will be made available via the Clinical Study Data Request Site,2018-08-01T21:15:35Z,2018-08-01T21:15:35Z
NCT03555396,"ClinicalTrials.gov processed this data on August 01, 2018",2018-06-01,NA,NA,2018-06-12,2018-06-12,2018-06-13,Actual,NA,NA,NA,NA,NA,NA,2018-06-12,2018-06-13,Actual,July 2018,Anticipated,2018-07-31,June 2018,2018-06-30,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Interventional,NA,,A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs,A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs in Kazakhstan,Not yet recruiting,NA,N/A,132,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,Unidentified data can be shared with other researchers in accordance with IRB regulations upon completion and analysis of the study.,2018-08-01T21:16:45Z,2018-08-01T21:16:45Z
NCT03529409,"ClinicalTrials.gov processed this data on August 01, 2018",2018-05-07,NA,NA,2018-05-17,2018-05-17,2018-05-18,Actual,NA,NA,NA,NA,NA,NA,2018-05-17,2018-05-18,Actual,July 2018,Anticipated,2018-07-31,May 2018,2018-05-31,January 2022,Anticipated,2022-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa,Hybrid Effectiveness-Implementation Trial for ART Adherence and Substance Use in HIV Care in South Africa,Not yet recruiting,NA,N/A,60,Anticipated,University of Maryland,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"After all primary analyses are complete, de-identified data will be available per request of outside individual.",2018-08-01T21:20:09Z,2018-08-01T21:20:09Z
NCT03516318,"ClinicalTrials.gov processed this data on August 01, 2018",2018-04-24,NA,NA,2018-05-10,2018-04-24,2018-05-04,Actual,NA,NA,NA,NA,NA,NA,2018-05-10,2018-05-16,Actual,"June 1, 2018",Anticipated,2018-06-01,May 2018,2018-05-31,"November 30, 2019",Anticipated,2019-11-30,"September 30, 2019",Anticipated,2019-09-30,NA,Interventional,Y-SMART,,Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria,Using Social Media to Improve ART Retention and Treatment (SMART) Outcomes Among Youth Living With HIV (YLHIV) in Nigeria - The Youth SMART Study,Not yet recruiting,NA,N/A,500,Anticipated,FHI 360,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"De-identified, quantitative data on study participants will be uploaded to the USAID Development Data Library.",2018-08-01T21:21:47Z,2018-08-01T21:21:47Z
NCT03515772,"ClinicalTrials.gov processed this data on August 01, 2018",2018-04-23,NA,NA,2018-05-03,2018-04-23,2018-05-04,Actual,NA,NA,NA,NA,NA,NA,2018-05-03,2018-05-08,Actual,"April 23, 2018",Actual,2018-04-23,May 2018,2018-05-31,"October 31, 2019",Anticipated,2019-10-31,"July 31, 2019",Anticipated,2019-07-31,NA,Observational,NA,,Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients,Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients From the Swiss HIV Cohort Study,Recruiting,NA,NA,60,Anticipated,Centre Hospitalier Universitaire Vaudois,,NA,6,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,Samples Without DNA,"
      Plasma samples
    ",Yes,The investigators will share anonymized IPD with colleagues interested upon motivated request,2018-08-01T21:21:51Z,2018-08-01T21:21:51Z
NCT03508310,"ClinicalTrials.gov processed this data on August 01, 2018",2018-04-16,NA,NA,2018-04-16,2018-04-16,2018-04-25,Actual,NA,NA,NA,NA,NA,NA,2018-04-16,2018-04-25,Actual,"June 1, 2016",Actual,2016-06-01,April 2018,2018-04-30,"May 17, 2017",Actual,2017-05-17,"March 30, 2017",Actual,2017-03-30,NA,Interventional,TCOM,,A Waiting Room-Delivered Video to Enhance Clinical Outcomes Among Persons Living With HIV,"A Waiting Room-Delivered Video to Enhance Antiretroviral Therapy Readiness, Adherence, and Retention in Care for Minority Persons Living With HIV Infection",Completed,NA,N/A,4003,Actual,Centers for Disease Control and Prevention,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"When appropriate, data sets will be made available to interested researchers following discussion with study team.",2018-08-01T21:22:49Z,2018-08-01T21:22:49Z
NCT03465852,"ClinicalTrials.gov processed this data on August 01, 2018",2018-03-08,NA,NA,2018-03-15,2018-03-08,2018-03-14,Actual,NA,NA,NA,NA,NA,NA,2018-03-15,2018-03-19,Actual,"December 15, 2018",Anticipated,2018-12-15,March 2018,2018-03-31,"July 15, 2020",Anticipated,2020-07-15,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,,HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention,HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention,Not yet recruiting,NA,N/A,140,Anticipated,Centers for Disease Control and Prevention,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"A plan agreed to by the Principal Investigator and the Centers for Disease Control and Prevention (CDC) will make, after approval by the CDC, the following study data available to applicants who provide detailed information on their reasons for requesting the data and plans analysis and use of the data:
Quantitative data from structured surveys for baseline and 6-month follow-up assessments;
Qualitative data from in-depth interviews with selected study participants to elucidate factors that contribute to or impede participant reports of engaging in the expected intervention outcomes following completion of the intervention (consistent condom use and use of PrEP and medically-supervised hormone therapy):
medical record abstractions, and data from biological markers including PrEP and HIV test results. None of the data described here will contain personal identifying information from study participants.",2018-08-01T21:28:36Z,2018-08-01T21:28:36Z
NCT03446573,"ClinicalTrials.gov processed this data on August 01, 2018",2018-01-05,NA,NA,2018-07-12,2018-02-19,2018-02-27,Actual,NA,NA,NA,NA,NA,NA,2018-07-12,2018-07-16,Actual,"January 18, 2018",Actual,2018-01-18,July 2018,2018-07-31,"January 31, 2021",Anticipated,2021-01-31,"June 14, 2019",Anticipated,2019-06-14,NA,Interventional,NA,,Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO),"A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed","Active, not recruiting",NA,Phase 3,550,Anticipated,ViiV Healthcare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Yes,IPD for this study will be made available via the Clinical Study Data Request Site,2018-08-01T21:31:12Z,2018-08-01T21:31:12Z
NCT03441984,"ClinicalTrials.gov processed this data on August 01, 2018",2018-02-15,NA,NA,2018-05-31,2018-02-15,2018-02-22,Actual,NA,NA,NA,NA,NA,NA,2018-05-31,2018-06-01,Actual,"February 26, 2018",Actual,2018-02-26,May 2018,2018-05-31,"April 28, 2018",Actual,2018-04-28,"April 28, 2018",Actual,2018-04-28,NA,Interventional,NA,,To Assess the Relative Bioavailability (BA) of TRIUMEQÂ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers,"A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers",Completed,NA,Phase 1,95,Actual,ViiV Healthcare,,12,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2018-08-01T21:31:47Z,2018-08-01T21:31:47Z
NCT03435146,"ClinicalTrials.gov processed this data on August 01, 2018",2017-08-21,NA,NA,2018-02-14,2018-02-14,2018-02-15,Actual,NA,NA,NA,NA,NA,NA,2018-02-14,2018-02-15,Actual,"January 18, 2018",Actual,2018-01-18,February 2018,2018-02-28,"November 3, 2018",Anticipated,2018-11-03,"October 31, 2018",Anticipated,2018-10-31,NA,Interventional,IMPAACT4TB,,Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients,"Safety, Tolerability and Drug-drug Interactions of Short Course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid Among HIV-infected Patients Taking Dolutegravir-based Antiretroviral Treatment",Recruiting,NA,Phase 1/Phase 2,60,Anticipated,The Aurum Institute NPC,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Yes,"To be shared amongst the collaborators on shared database when study starts and is complete.
Results will be disseminated via conferences and publication by scientific peer reviewed journal(s)",2018-08-01T21:32:41Z,2018-08-01T21:32:41Z
NCT03422172,"ClinicalTrials.gov processed this data on August 01, 2018",2018-01-30,NA,NA,2018-06-18,2018-01-30,2018-02-05,Actual,NA,NA,NA,NA,NA,NA,2018-06-18,2018-06-19,Actual,"April 10, 2018",Actual,2018-04-10,June 2018,2018-06-30,"March 7, 2020",Anticipated,2020-03-07,"March 7, 2020",Anticipated,2020-03-07,NA,Interventional,NA,,"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men",Recruiting,NA,Phase 1,48,Anticipated,ViiV Healthcare,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2018-08-01T21:34:30Z,2018-08-01T21:34:30Z
NCT03404531,"ClinicalTrials.gov processed this data on August 01, 2018",2018-01-12,NA,NA,2018-01-31,2018-01-12,2018-01-19,Actual,NA,NA,NA,NA,NA,NA,2018-01-31,2018-02-02,Estimate,"November 10, 2017",Actual,2017-11-10,January 2018,2018-01-31,"April 30, 2020",Anticipated,2020-04-30,"April 30, 2019",Anticipated,2019-04-30,NA,Interventional,MAP,,Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media,Reaching Black/African American and Hispanic/Latino MSM Through Social Media About Treatment as Prevention and Pre-Exposure Prophylaxis,Recruiting,NA,N/A,164,Anticipated,Brown University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"Research data will be shared openly, proactively, and timely in accordance with the most recent NIH guidelines (http://grants.nih.gov/grants/policy/data_sharing/) while being mindful that the confidentiality and privacy of participants in research must be protected at all times. Specific plans to share data, including an overview of what will be shared, when it will be shared, how it will be shared, and who will have access to the data will be proposed in a data sharing agreement that all investigators and prospective users of the data will complete when requesting access to the data.",2018-08-01T21:37:12Z,2018-08-01T21:37:12Z
NCT03397420,"ClinicalTrials.gov processed this data on August 01, 2018",2018-01-02,NA,NA,2018-01-05,2018-01-05,2018-01-12,Actual,NA,NA,NA,NA,NA,NA,2018-01-05,2018-01-12,Actual,"September 13, 2017",Actual,2017-09-13,September 2017,2017-09-30,"June 30, 2019",Anticipated,2019-06-30,"June 30, 2018",Anticipated,2018-06-30,NA,Interventional,FAM-CARE,,"Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland",Effect of Family-centered Model of HIV Care (FAM-CARE) on Viral Suppression and Retention in Care of HIV-positive Children in Swaziland,Recruiting,NA,N/A,660,Anticipated,Elizabeth Glaser Pediatric AIDS Foundation,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,All collected IPDs,2018-08-01T21:38:16Z,2018-08-01T21:38:16Z
NCT03394196,"ClinicalTrials.gov processed this data on August 01, 2018",2017-12-14,NA,NA,2018-07-24,2018-01-05,2018-01-09,Actual,NA,NA,NA,NA,NA,NA,2018-07-24,2018-07-26,Actual,"July 4, 2018",Actual,2018-07-04,July 2018,2018-07-31,July 2021,Anticipated,2021-07-31,January 2021,Anticipated,2021-01-31,NA,Interventional,RESIST-2,,RESIST-2: 2nd-line ART for HIV-2 Infection,Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative SÃ©nÃ©galaise d'AccÃ¨s Aux AntirÃ©troviraux (ISAARV) Program,Recruiting,NA,N/A,150,Anticipated,University of Washington,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Yes,IPD shared on request with ORB approval on final cleaned dataset,2018-08-01T21:38:40Z,2018-08-01T21:38:40Z
NCT03384784,"ClinicalTrials.gov processed this data on August 01, 2018",2017-12-08,NA,NA,2018-07-26,2017-12-19,2017-12-27,Actual,NA,NA,NA,NA,NA,NA,2018-07-26,2018-07-27,Actual,"October 30, 2017",Actual,2017-10-30,July 2018,2018-07-31,May 2022,Anticipated,2022-05-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CHI,,Effect of Galantamine on Inflammation and Cognition,Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction,Recruiting,NA,Phase 2,150,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,Yes,"The final dataset will include demographic and behavioral assessments and laboratory data bio-specimens. Because the dataset will contain personal health information, identifying information will be collected. Even though the final dataset will be stripped of identifiers prior to release for sharing, investigators will do the following to reduce the possibility confidentiality loss. We will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
Transcriptomic data will be deposited with a public access database such as NCBI's Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/)",2018-08-01T21:40:08Z,2018-08-01T21:40:08Z
NCT03383211,"ClinicalTrials.gov processed this data on August 01, 2018",2017-12-19,NA,NA,2017-12-19,2017-12-19,2017-12-26,Actual,NA,NA,NA,NA,NA,NA,2017-12-19,2017-12-26,Actual,"June 16, 2017",Actual,2017-06-16,December 2017,2017-12-31,"June 30, 2022",Anticipated,2022-06-30,"September 1, 2018",Anticipated,2018-09-01,NA,Observational,IMMUNEO,,Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers,Transcriptomic Profile of the Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers,Recruiting,NA,NA,150,Anticipated,George Washington University,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      RNA isolated from peripheral blood.
    ",Yes,Genomic data will be submitted to the NCBI SRA archive,2018-08-01T21:40:23Z,2018-08-01T21:40:23Z
NCT03368053,"ClinicalTrials.gov processed this data on August 01, 2018",2017-12-05,NA,NA,2018-05-04,2017-12-05,2017-12-11,Actual,NA,NA,NA,NA,NA,NA,2018-05-04,2018-05-07,Actual,"December 14, 2017",Actual,2017-12-14,May 2018,2018-05-31,"January 30, 2018",Actual,2018-01-30,"January 30, 2018",Actual,2018-01-30,NA,Interventional,NA,,Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461),Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461),Completed,NA,Phase 1,36,Actual,GlaxoSmithKline,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2018-08-01T21:43:00Z,2018-08-01T21:43:00Z
NCT03353701,"ClinicalTrials.gov processed this data on August 01, 2018",2017-11-03,NA,NA,2018-06-29,2017-11-20,2017-11-27,Actual,NA,NA,NA,NA,NA,NA,2018-06-29,2018-07-02,Actual,"December 11, 2017",Actual,2017-12-11,June 2018,2018-06-30,December 2020,Anticipated,2020-12-31,October 2019,Anticipated,2019-10-31,NA,Interventional,NA,,30-to-90 Day Challenge: Effects of Alcohol Cessation on Health Outcomes,"Effects of Experimentally-induced Reductions in Alcohol Consumption on Brain Cognitive and Clinical Outcomes, and Motivation for Changing Drinking in Older Persons With HIV Infection",Recruiting,NA,N/A,180,Anticipated,University of Florida,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,Limited and de-identified datasets will be available to researchers after signing a data-use agreement with the University of Florida.,2018-08-01T21:44:51Z,2018-08-01T21:44:51Z
NCT03312244,"ClinicalTrials.gov processed this data on August 01, 2018",2017-04-01,NA,NA,2017-10-16,2017-10-16,2017-10-17,Actual,NA,NA,NA,NA,NA,NA,2017-10-16,2017-10-17,Actual,"October 1, 2017",Actual,2017-10-01,October 2017,2017-10-31,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2019",Anticipated,2019-06-30,NA,Interventional,NA,,Pyridostigmine as Immunomodulator in People Living With HIV,Study of the Role of Peripheral Acetylcholinesterase Inhibitor Pyridostigmine as Immunomodulators in a Population of Patients Living With Human Immunodeficiency Virus Infection.,"Active, not recruiting",NA,Phase 2,60,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Yes,All data will be freely available to all research parties involved,2018-08-01T21:50:45Z,2018-08-01T21:50:45Z
NCT03278886,"ClinicalTrials.gov processed this data on August 01, 2018",2017-09-05,NA,NA,2018-07-02,2017-09-08,2017-09-12,Actual,NA,NA,NA,NA,NA,NA,2018-07-02,2018-07-03,Actual,"July 3, 2018",Actual,2018-07-03,July 2018,2018-07-31,February 2019,Anticipated,2019-02-28,February 2019,Anticipated,2019-02-28,NA,Interventional,PETER PAIN,,St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene,Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems,Recruiting,NA,Phase 1/Phase 2,16,Anticipated,Boston Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,All data from the study will be placed into the URBAN ARCH repository.,2018-08-01T21:55:42Z,2018-08-01T21:55:42Z
NCT03275701,"ClinicalTrials.gov processed this data on August 01, 2018",2016-07-22,NA,NA,2017-09-05,2017-09-05,2017-09-07,Actual,NA,NA,NA,NA,NA,NA,2017-09-05,2017-09-07,Actual,July 2016,NA,2016-07-31,September 2017,2017-09-30,November 2019,Anticipated,2019-11-30,October 2019,Anticipated,2019-10-31,NA,Interventional,STRUCTR,,Evaluating BMD in Participants â‰¥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC,"Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults â‰¥50 Years Old Switching From EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)",Recruiting,NA,N/A,50,Anticipated,Mills Clinical Research,,1,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,NA,2018-08-01T21:56:11Z,2018-08-01T21:56:11Z
NCT03235349,"ClinicalTrials.gov processed this data on August 01, 2018",2017-07-28,NA,NA,2018-07-13,2017-07-28,2017-08-01,Actual,NA,NA,NA,NA,NA,NA,2018-07-13,2018-07-17,Actual,"September 29, 2017",Actual,2017-09-29,July 2018,2018-07-31,"March 8, 2019",Anticipated,2019-03-08,"December 5, 2018",Anticipated,2018-12-05,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment- Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection,An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-NaÃ¯ve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection,"Active, not recruiting",NA,Phase 3,159,Actual,AbbVie,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2018-08-01T22:02:22Z,2018-08-01T22:02:22Z
NCT03215901,"ClinicalTrials.gov processed this data on August 01, 2018",2017-07-06,NA,NA,2018-01-10,2017-07-06,2017-07-12,Actual,NA,NA,NA,NA,NA,NA,2018-01-10,2018-01-11,Actual,"September 6, 2017",Actual,2017-09-06,January 2018,2018-01-31,"December 14, 2017",Actual,2017-12-14,"December 14, 2017",Actual,2017-12-14,NA,Interventional,NA,,Life Plans Intervention Study,Life Plans of Young Adults in Rural KwaZulu-Natal: an Intervention Study,Completed,NA,N/A,430,Actual,Boston University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,De-identified data will be archived on the Africa Health Research Institute repository and will be available via a data request.,2018-08-01T22:05:25Z,2018-08-01T22:05:25Z
NCT03198325,"ClinicalTrials.gov processed this data on August 01, 2018",2017-06-21,NA,NA,2017-06-22,2017-06-22,2017-06-26,Actual,NA,NA,NA,NA,NA,NA,2017-06-22,2017-06-26,Actual,"July 27, 2016",Actual,2016-07-27,June 2017,2017-06-30,April 2018,Anticipated,2018-04-30,December 2017,Anticipated,2017-12-31,NA,Interventional,APACHE,,Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia,Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia (APACHE Study),Recruiting,NA,N/A,30,Anticipated,Ospedale San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,Congress and scientific pubblications,2018-08-01T22:08:20Z,2018-08-01T22:08:20Z
NCT03149757,"ClinicalTrials.gov processed this data on August 01, 2018",2017-05-09,NA,NA,2018-07-11,2017-05-09,2017-05-11,Actual,NA,NA,NA,NA,NA,NA,2018-07-11,2018-07-13,Actual,"May 16, 2017",Actual,2017-05-16,July 2018,2018-07-31,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial,Connecting Youth and Young Adults to Optimize ART Adherence: Testing the Efficacy of the Youth Thrive Intervention,Recruiting,NA,Phase 2,300,Anticipated,University of Minnesota - Clinical and Translational Science Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the data set. The de-identified data from this project will be available through individual requests directed to the Principal Investigator.",2018-08-01T22:16:16Z,2018-08-01T22:16:16Z
NCT03147859,"ClinicalTrials.gov processed this data on August 01, 2018",2017-04-03,NA,NA,2017-11-17,2017-05-08,2017-05-10,Actual,NA,NA,NA,NA,NA,NA,2017-11-17,2017-11-21,Actual,"November 1, 2017",Actual,2017-11-01,November 2017,2017-11-30,"December 31, 2018",Anticipated,2018-12-31,"December 31, 2018",Anticipated,2018-12-31,NA,Interventional,HAVARTI,,Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection,Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection,Recruiting,NA,Phase 2,12,Anticipated,Ottawa Hospital Research Institute,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"Study dataset, after study closure and publication, by request.",2018-08-01T22:16:32Z,2018-08-01T22:16:32Z
NCT03134924,"ClinicalTrials.gov processed this data on August 01, 2018",2017-04-21,NA,NA,2017-04-28,2017-04-28,2017-05-01,Actual,NA,NA,NA,NA,NA,NA,2017-04-28,2017-05-01,Actual,"May 3, 2013",Actual,2013-05-03,April 2017,2017-04-30,"February 5, 2014",Actual,2014-02-05,"February 5, 2014",Actual,2014-02-05,NA,Interventional,NA,,"Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention ""WASH-2""","Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention ""WASH-2""",Completed,NA,N/A,128,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,Available from the PI upon request.,2018-08-01T22:18:33Z,2018-08-01T22:18:33Z
NCT03132415,"ClinicalTrials.gov processed this data on August 01, 2018",2017-04-24,NA,NA,2018-05-21,2017-04-24,2017-04-27,Actual,NA,NA,NA,NA,NA,NA,2018-05-21,2018-05-23,Actual,"November 1, 2017",Actual,2017-11-01,May 2018,2018-05-31,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,NA,,Get Connected Efficacy Trial,"Get Connected: Linking YMSM to Adequate Care Through a Multilevel, Tailored WebApp Intervention",Recruiting,NA,N/A,480,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the dataset. The de-identified data from this project will be available through individual requests directed to the Principal Investigator.",2018-08-01T22:19:01Z,2018-08-01T22:19:01Z
NCT03100331,"ClinicalTrials.gov processed this data on August 01, 2018",2017-03-20,NA,NA,2018-04-26,2017-03-28,2017-04-04,Actual,NA,NA,NA,NA,NA,NA,2018-04-26,2018-04-30,Actual,"January 13, 2017",Actual,2017-01-13,April 2018,2018-04-30,"January 13, 2020",Anticipated,2020-01-13,"January 13, 2020",Anticipated,2020-01-13,NA,Interventional,NA,,Neuropsychological Outcomes of Internationally-Adopted Children Who Are Perinatally-Infected With Human Immunodeficiency Virus,Neuropsychological Outcomes of Internationally-Adopted Children Who Are Perinatally-Infected With Human Immunodeficiency Virus,"Active, not recruiting",NA,N/A,17,Actual,Spectrum Health Hospitals,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,We may share the data with future co-investigators at the NIH Peds HIV observational cohort study,2018-08-01T22:24:24Z,2018-08-01T22:24:24Z
NCT03090802,"ClinicalTrials.gov processed this data on August 01, 2018",2017-03-16,NA,NA,2017-12-14,2017-03-21,2017-03-27,Actual,NA,NA,NA,NA,NA,NA,2017-12-14,2017-12-18,Actual,"June 26, 2017",Actual,2017-06-26,December 2017,2017-12-31,"September 30, 2018",Anticipated,2018-09-30,"September 30, 2018",Anticipated,2018-09-30,NA,Interventional,MAMAS,,MAMAS: Mentoring Adolescent Mothers at School,Re-enrolling Young South African Mothers in School as a Social Vaccine Against HIV Transmission,Recruiting,NA,N/A,480,Anticipated,Drexel University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"Persons requesting permission to access non-biological data (behavioral assessments) will communicate with the project PI, Dr. Ali Groves, who will provide/decline permission. Persons requesting permission to access biological data (biological assessments and specimens) will communicate with the site PI, Dr. Daya Moodley, who will provide/decline permission. If permission is granted, the relevant research staff will be alerted to the release of samples/data as requested. A list of the participant samples/data being released will be provided to the PI, and the person requesting the data. Both will acknowledge release and receipt of samples/data. Data that will be provided with the samples will be limited to demographic data, no personal participant information will be provided; only participant identifiers will be used to identify the specific sample/data requested.",2018-08-01T22:26:01Z,2018-08-01T22:26:01Z
NCT03066128,"ClinicalTrials.gov processed this data on August 01, 2018",2017-02-22,NA,NA,2018-05-01,2017-02-23,2017-02-28,Actual,NA,NA,NA,NA,NA,NA,2018-05-01,2018-05-07,Actual,"February 24, 2017",Actual,2017-02-24,May 2018,2018-05-31,"March 27, 2019",Anticipated,2019-03-27,"September 27, 2018",Anticipated,2018-09-27,NA,Interventional,STREAM,,Point-of-care Viral Load Testing to Enable Streamlined Care and Task Shifting for Chronic HIV Care,Point-of-care Viral Load Testing to Enable Streamlined Care and Task Shifting for Chronic HIV Care,"Active, not recruiting",NA,N/A,390,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,De-identified individual participant data for all outcome measures will be made available after study completion,2018-08-01T22:29:59Z,2018-08-01T22:29:59Z
NCT03051789,"ClinicalTrials.gov processed this data on August 01, 2018",2017-02-09,NA,NA,2018-03-12,2017-02-13,2017-02-14,Actual,NA,NA,NA,NA,NA,NA,2018-03-12,2018-03-13,Actual,"February 28, 2017",Actual,2017-02-28,March 2018,2018-03-31,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,NA,Interventional,CCg,,Cups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School Dropout,Menstrual Cups and Cash Transfer to Reduce Sexual and Reproductive Harm and School Dropout in Adolescent Schoolgirls in Western Kenya: a Cluster Randomised Controlled Trial,Recruiting,NA,N/A,3864,Anticipated,Liverpool School of Tropical Medicine,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Yes,"A link will be provided from LSTM and study-specific website to study resources including the protocol, participant information sheets, SOPs, publications and the database. A data repository is being established at LSTM and will be entrusted with storing data when ready. The investigators policy to data sharing will be published on the study website. A final database containing all research data will be made fully publicly available in an unrestricted format once the findings have been published. The only limits to data sharing will be to safeguard participants' confidentiality. The proposed procedures for data sharing will be set out and explained to the research participants as part of the informed consent process. External users will be bound by data sharing agreements in line with The MRC Data Sharing Policy. External users will be required to accept terms and conditions of use using a declaration tick box.",2018-08-01T22:32:37Z,2018-08-01T22:32:37Z
NCT03049176,"ClinicalTrials.gov processed this data on August 01, 2018",2017-02-07,NA,NA,2017-04-18,2017-02-07,2017-02-09,Estimate,NA,NA,NA,NA,NA,NA,2017-04-18,2017-04-19,Actual,"March 13, 2017",Actual,2017-03-13,April 2017,2017-04-30,March 2019,Anticipated,2019-03-31,April 2018,Anticipated,2018-04-30,NA,Observational,SAFER,,The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER),The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples,Recruiting,NA,NA,160,Anticipated,"University of California, San Francisco",,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,De-identified data will be made available at the end of the study on an online repository.,2018-08-01T22:33:02Z,2018-08-01T22:33:02Z
NCT03037372,"ClinicalTrials.gov processed this data on August 01, 2018",2017-01-10,NA,NA,2017-01-26,2017-01-26,2017-01-31,Estimate,NA,NA,NA,NA,NA,NA,2017-01-26,2017-01-31,Estimate,"June 1, 2017",Anticipated,2017-06-01,January 2017,2017-01-31,"December 31, 2022",Anticipated,2022-12-31,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,STAR,,Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial,Statin Adjunct Therapy Among HAART-treated Adults in Sub-Saharan Africa: Equivalence of Atorvastatin and Rosuvastatin,Not yet recruiting,NA,Phase 3,320,Anticipated,Makerere University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Yes,"Data will be shared with the Infectious Diseases Institute, according to the IDI data sharing policy",2018-08-01T22:35:04Z,2018-08-01T22:35:04Z
NCT03033836,"ClinicalTrials.gov processed this data on August 01, 2018",2016-08-18,NA,NA,2017-08-09,2017-01-24,2017-01-27,Estimate,NA,NA,NA,NA,NA,NA,2017-08-09,2017-08-10,Actual,December 2015,NA,2015-12-31,August 2017,2017-08-31,December 2017,Anticipated,2017-12-31,October 2017,Anticipated,2017-10-31,NA,Interventional,TRANSViiV,,Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women,Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women,Recruiting,NA,Phase 4,60,Anticipated,The Huesped Foundation,,1,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,to publish study results,2018-08-01T22:35:45Z,2018-08-01T22:35:45Z
NCT03030768,"ClinicalTrials.gov processed this data on August 01, 2018",2017-01-12,NA,NA,2017-11-01,2017-01-20,2017-01-25,Estimate,NA,NA,NA,NA,NA,NA,2017-11-01,2017-11-06,Actual,February 2016,NA,2016-02-29,November 2017,2017-11-30,August 2018,Anticipated,2018-08-31,June 2018,Anticipated,2018-06-30,NA,Observational,SCIP,,Safer Conception Intervention for HIV-1 Serodiscordant Couples,"Pilot of an mHealth-enhanced, Safer Conception Intervention to Reduce HIV-1 Risk Among Kenyan HIV-1 Serodiscordant Couples","Active, not recruiting",NA,NA,74,Actual,University of Washington,,NA,1,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,"
      Plasma
    ",Yes,De-identified individual participant data for all outcome measures will be made available after study completion,2018-08-01T22:36:15Z,2018-08-01T22:36:15Z
NCT03024762,"ClinicalTrials.gov processed this data on August 01, 2018",2016-12-06,NA,NA,2017-01-22,2017-01-15,2017-01-19,Estimate,NA,NA,NA,NA,NA,NA,2017-01-22,2017-01-24,Estimate,July 2015,Actual,2015-07-31,January 2017,2017-01-31,December 2018,Anticipated,2018-12-31,December 2016,Actual,2016-12-31,NA,Interventional,ASPA,,Active Search for Pediatric HIV/AIDS (ASPA),Active Search for Pediatric HIV/AIDS (ASPA),"Active, not recruiting",NA,N/A,870,Anticipated,Research for Development International,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Data can be made available to other researchers through an application addressed to the sponsor (Research for Development International) and this via the Principal Investigator (Dr Yumo Habakkuk).,2018-08-01T22:37:10Z,2018-08-01T22:37:10Z
NCT03004170,"ClinicalTrials.gov processed this data on August 01, 2018",2016-12-20,NA,NA,2018-04-03,2016-12-22,2016-12-28,Estimate,NA,NA,NA,NA,NA,NA,2018-04-03,2018-04-05,Actual,December 2016,Actual,2016-12-31,April 2018,2018-04-30,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,NA,Interventional,NA,,Telephone Counseling to Enhance the Quality and Safety of Romantic and Sexual Relationships in People Living and Aging With HIV,NA,Recruiting,NA,N/A,336,Anticipated,Oregon Health and Science University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Raw de-identified data will be made publicly available to the scientific community upon request after the trial is complete and data have been published. Data requests should be directed to the study principal investigator.,2018-08-01T22:40:33Z,2018-08-01T22:40:33Z
NCT03002012,"ClinicalTrials.gov processed this data on August 01, 2018",2016-12-14,NA,NA,2018-03-20,2016-12-20,2016-12-23,Estimate,NA,NA,NA,NA,NA,NA,2018-03-20,2018-03-22,Actual,"November 15, 2017",Actual,2017-11-15,March 2018,2018-03-31,"March 13, 2018",Actual,2018-03-13,"March 13, 2018",Actual,2018-03-13,NA,Interventional,C-ASSERT,,Cryptococcal Antigen Screening Plus Sertraline,Cryptococcal Antigen Screening Plus Sertraline,Terminated,NA,Phase 3,21,Actual,University of Minnesota - Clinical and Translational Science Institute,,2,NA,"SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Yes,A formal written data sharing plan exists. No data will be shared until after trial completion.,2018-08-01T22:40:51Z,2018-08-01T22:40:51Z
NCT02994329,"ClinicalTrials.gov processed this data on August 01, 2018",2016-11-30,NA,NA,2018-01-11,2016-12-14,2016-12-15,Estimate,NA,NA,NA,NA,NA,NA,2018-01-11,2018-01-16,Actual,"January 18, 2017",Actual,2017-01-18,January 2018,2018-01-31,"September 30, 2017",Actual,2017-09-30,"September 30, 2017",Actual,2017-09-30,NA,Interventional,NA,,Community-based Distribution of Oral HIV Self-testing Kits,Community-based Distribution of Oral HIV Self-testing Kits-A Pilot Intervention and Rapid Impact Evaluation,Completed,NA,N/A,8080,Actual,Zambart,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,the de-identified data will be made available via International Initiative for Evaluation's (3ie) public access data repository.,2018-08-01T22:42:11Z,2018-08-01T22:42:11Z
NCT02969915,"ClinicalTrials.gov processed this data on August 01, 2018",2016-11-18,NA,NA,2017-12-19,2016-11-18,2016-11-21,Estimate,NA,NA,NA,NA,NA,NA,2017-12-19,2017-12-21,Actual,"October 30, 2017",Actual,2017-10-30,December 2017,2017-12-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Strategies to Improve the HIV Care Continuum Among Key Populations in India,Strategies to Improve the HIV Care Continuum Among Key Populations in India,Recruiting,NA,N/A,18400,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"The investigators will require prospective collaborators to submit concept sheets to the study PIs that include a brief summary of the proposed hypothesis, summary of research methods, specific data or specimens that are being requested, and plans for analysis. Reasonable requests that address relevant scientific questions will be welcomed and supported to the extent possible.",2018-08-01T22:46:46Z,2018-08-01T22:46:46Z
NCT02965014,"ClinicalTrials.gov processed this data on August 01, 2018",2016-11-14,NA,NA,2018-02-07,2016-11-15,2016-11-16,Estimate,NA,NA,NA,NA,NA,NA,2018-02-07,2018-02-09,Actual,"January 18, 2017",Actual,2017-01-18,February 2018,2018-02-28,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,NC Young Women's CoOp,Young Women-Focused HIV Prevention: Seek & Test in North Carolina (NC) Clinics,Recruiting,NA,N/A,700,Anticipated,RTI International,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Yes,"Analytic data sets will be prepared in accordance with the ""Privacy Rule"" of the Health Insurance Portability and Accountability Act (HIPAA; http://www.hhs.gov/ocr/) as ""limited data sets"" in which names and other personal health identifiers are removed, birthdays have been converted to age at intake, and other dates have been changed to be days before or after the date of intake. Because there are fewer than 20,000 people in the data set, HIPAA says we cannot ensure that it is completely ""de-identified""; consequently, HIPAA requires that we treat it as a ""limited data set"" and that we have a data sharing agreement (DSA) in place before giving anyone access to the client-level data. After the main findings are published, we will welcome other researchers who want to analyze the data in other ways. Requesting access to data will involve drafting an abstract, checking the feasibility relative to the available data, and seeking the permission of the PI and her team.",2018-08-01T22:47:44Z,2018-08-01T22:47:44Z
NCT02949713,"ClinicalTrials.gov processed this data on August 01, 2018",2016-10-26,NA,NA,2016-10-27,2016-10-27,2016-10-31,Estimate,NA,NA,NA,NA,NA,NA,2016-10-27,2016-10-31,Estimate,June 2017,NA,2017-06-30,October 2016,2016-10-31,February 2018,Anticipated,2018-02-28,February 2018,Anticipated,2018-02-28,NA,Interventional,NA,,Text Messaging Plus Motivational Interviewing in Promotion of Breastfeeding Among HIV-infected Women,"Feasibility and Effects of Mobile Phone Text Messaging Plus Motivational Interviewing Versus Usual Care in Promotion of Breastfeeding Among HIV-infected Women in South Africa: A Randomized, Parallel Group, Controlled Pilot Trial",Not yet recruiting,NA,N/A,84,Anticipated,University of Stellenbosch,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,The IPD will be available from the corresponding author on reasonable request,2018-08-01T22:50:40Z,2018-08-01T22:50:40Z
NCT02891720,"ClinicalTrials.gov processed this data on August 01, 2018",2016-08-29,NA,NA,2016-09-01,2016-09-01,2016-09-07,Estimate,NA,NA,NA,NA,NA,NA,2016-09-01,2016-09-07,Estimate,June 2017,NA,2017-06-30,September 2016,2016-09-30,November 2019,Anticipated,2019-11-30,November 2018,Anticipated,2018-11-30,NA,Interventional,NA,,Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM,Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM,Not yet recruiting,NA,N/A,100,Anticipated,Hektoen Institute for Medical Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"Findings from this study will provide pharmacokinetic data along with evidence of the feasibility and acceptability of the novel Proteus adherence monitoring system for use among young MSM who are highly vulnerable to HIV infection. Audiences for dissemination are: 1) scientists; 2) primary and secondary prevention practitioners; and 3) YMSM, their partners, and their friends/families. Traditional dissemination vehicles will be used including manuscripts and presentations at international and national meetings. To facilitate integration of the findings into the public health arena, the protocol team will work closely with their YAB and present findings in forums attended by community-based organizations, such as local PrEP trainings and workshops.",2018-08-01T23:03:25Z,2018-08-01T23:03:25Z
NCT02886416,"ClinicalTrials.gov processed this data on August 01, 2018",2016-08-29,NA,NA,2016-09-01,2016-08-29,2016-09-01,Estimate,NA,NA,NA,NA,NA,NA,2016-09-01,2016-09-02,Estimate,September 2016,NA,2016-09-30,September 2016,2016-09-30,September 2018,Anticipated,2018-09-30,September 2017,Anticipated,2017-09-30,NA,Observational,"""ImmunoCo27""",,Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity,"Study of Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity, for 27 Years of Natural Evolution and on Treatment",Not yet recruiting,NA,NA,28,Anticipated,French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS),,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples With DNA,"
      frozen PBMC
    ",Yes,Scientific publication,2018-08-01T23:04:24Z,2018-08-01T23:04:24Z
NCT02850276,"ClinicalTrials.gov processed this data on August 01, 2018",2016-07-27,NA,NA,2017-07-21,2016-07-27,2016-07-29,Estimate,NA,NA,NA,NA,NA,NA,2017-07-21,2017-07-25,Actual,November 2015,NA,2015-11-30,July 2017,2017-07-31,March 2018,Anticipated,2018-03-31,March 2018,Anticipated,2018-03-31,NA,Interventional,ANGI,,"Autonomic Neuropathy, GI Motility, and Inflammation in HIV","Autonomic Neuropathy, Gastrointestinal Motility, and Inflammation in HIV",Recruiting,NA,Early Phase 1,45,Anticipated,Icahn School of Medicine at Mount Sinai,,1,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Data will be shared with participants in real time if the tests have any clinical significance.,2018-08-01T23:10:33Z,2018-08-01T23:10:33Z
NCT02842060,"ClinicalTrials.gov processed this data on August 01, 2018",2016-07-16,NA,NA,2017-05-09,2016-07-21,2016-07-22,Estimate,NA,NA,NA,NA,NA,NA,2017-05-09,2017-05-10,Actual,November 2016,Actual,2016-11-30,May 2017,2017-05-31,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,NA,Interventional,myDEx,,Development of a Tailored HIV Prevention Intervention for Young Men,Development of a Tailored HIV Prevention Intervention for Young Men,Completed,NA,N/A,180,Actual,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the dataset. The de-identified data from this project will be available through individual requests directed to the Principal Investigator.",2018-08-01T23:11:57Z,2018-08-01T23:11:57Z
NCT02827240,"ClinicalTrials.gov processed this data on August 01, 2018",2016-06-30,NA,NA,2018-05-02,2016-07-05,2016-07-11,Estimate,NA,NA,NA,NA,NA,NA,2018-05-02,2018-05-07,Actual,August 2016,Actual,2016-08-31,May 2018,2018-05-31,June 2017,Actual,2017-06-30,March 2017,Actual,2017-03-31,NA,Interventional,ZEST,,Zambian Peer-Educators for HIV Self-Testing Study,A Peer Educator-delivered HIV Self-testing Intervention for Female Sex Workers in Zambian Border Towns,Completed,NA,N/A,965,Actual,Harvard School of Public Health,,3,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,De-identified data will be made available via International Initiative for Impact Evaluation's public access data repository.,2018-08-01T23:14:28Z,2018-08-01T23:14:28Z
NCT02817451,"ClinicalTrials.gov processed this data on August 01, 2018",2016-06-27,NA,NA,2018-05-15,2016-06-27,2016-06-29,Estimate,NA,NA,NA,NA,NA,NA,2018-05-15,2018-05-18,Actual,"July 14, 2016",Actual,2016-07-14,May 2018,2018-05-31,"August 30, 2020",Anticipated,2020-08-30,"September 11, 2018",Anticipated,2018-09-11,NA,Interventional,NA,,DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a 2nd Year of Life Booster in HIV-Exposed Infected and Uninfected Infants,Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infants in Republic of South Africa,"Active, not recruiting",NA,Phase 3,100,Actual,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi"".",2018-08-01T23:16:19Z,2018-08-01T23:16:19Z
NCT02797587,"ClinicalTrials.gov processed this data on August 01, 2018",2016-06-08,NA,NA,2018-06-20,2016-06-08,2016-06-13,Estimate,NA,NA,NA,NA,NA,NA,2018-06-20,2018-06-25,Actual,"July 19, 2017",Actual,2017-07-19,June 2018,2018-06-30,December 2020,Anticipated,2020-12-31,April 2020,Anticipated,2020-04-30,NA,Interventional,St PETER HIV,,Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV),URBAN ARCH 4/5 Russia Cohort-Targeting HIV-comorbidities With Pharmacotherapy to Reduce Alcohol and Tobacco Use in HIV-infected Russians,Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Boston Medical Center,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,All data from the study will be placed into the URBAN ARCH repository.,2018-08-01T23:19:56Z,2018-08-01T23:19:56Z
NCT02775929,"ClinicalTrials.gov processed this data on August 01, 2018",2016-05-10,NA,NA,2017-12-07,2016-05-14,2016-05-18,Estimate,NA,NA,NA,NA,NA,NA,2017-12-07,2017-12-08,Actual,November 2012,NA,2012-11-30,December 2017,2017-12-31,June 2016,Actual,2016-06-30,June 2016,Actual,2016-06-30,NA,Interventional,NA,,Partners Demonstration Project of PrEP and ART,"An Open Label, Pilot Demonstration and Evaluation Project of Antiretroviral-based HIV-1 Prevention Among High-risk Serodiscordant African Couples",Completed,NA,Phase 4,1013,Actual,University of Washington,,1,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Data from the Partners Demonstration Project are available by contacting the International Clinical Research Center at the University of Washington (icrc@uw.edu).,2018-08-01T23:24:12Z,2018-08-01T23:24:12Z
NCT02756208,"ClinicalTrials.gov processed this data on August 01, 2018",2016-04-17,NA,NA,2017-08-02,2016-04-26,2016-04-29,Estimate,NA,NA,NA,NA,NA,NA,2017-08-02,2017-08-03,Actual,November 2015,Actual,2015-11-30,August 2017,2017-08-31,July 2018,Anticipated,2018-07-31,July 2018,Anticipated,2018-07-31,NA,Interventional,FLSC-001,,A Safety and Immunogenicity Trial of IHV01,A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers,"Active, not recruiting",NA,Phase 1,60,Anticipated,University of Maryland,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,,Yes,NA,2018-08-01T23:28:06Z,2018-08-01T23:28:06Z
NCT02741128,"ClinicalTrials.gov processed this data on August 01, 2018",2016-04-08,NA,NA,2017-06-28,2016-04-12,2016-04-18,Estimate,NA,NA,NA,NA,NA,NA,2017-06-28,2017-06-29,Actual,"March 20, 2019",Anticipated,2019-03-20,June 2017,2017-06-30,"March 18, 2021",Anticipated,2021-03-18,"March 18, 2021",Anticipated,2021-03-18,NA,Interventional,NA,,Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults,Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil,Not yet recruiting,NA,Phase 2,150,Anticipated,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Yes,Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com,2018-08-01T23:31:18Z,2018-08-01T23:31:18Z
NCT02707926,"ClinicalTrials.gov processed this data on August 01, 2018",2016-03-03,NA,NA,2017-09-20,2016-03-08,2016-03-14,Estimate,NA,NA,NA,NA,NA,NA,2017-09-20,2017-09-25,Actual,September 2018,Anticipated,2018-09-30,September 2017,2017-09-30,June 2021,Anticipated,2021-06-30,June 2020,Anticipated,2020-06-30,NA,Observational,NA,,The Lymphoid Tissue Pharmacology of Antiretroviral Drugs,The Lymphoid Tissue Pharmacology of Antiretroviral Drugs,Not yet recruiting,NA,NA,18,Anticipated,University of Nebraska,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,"
      Blood, urine, lymph node biopsy, colonoscopy biopsy of ileum and rectum
    ",Yes,"The results of this trial will be of interest to the HIV research and medical communities. We expect to submit the data from the main analysis within 6 months of completing the work. We will publish the results in a major scientific journal and present the results at a major scientific meeting (e.g., CROI). Subsequent analyses will be presented at national and international HIV meetings. Data generated under this project, and any intellectual property, will be administered in accordance with NIH policies, including the NIH Data Sharing Policy the NIH Public Access Policy.",2018-08-01T23:38:00Z,2018-08-01T23:38:00Z
NCT02696824,"ClinicalTrials.gov processed this data on August 01, 2018",2016-02-18,NA,NA,2018-02-16,2016-02-25,2016-03-02,Estimate,NA,NA,NA,NA,NA,NA,2018-02-16,2018-02-20,Estimate,March 2016,NA,2016-03-31,February 2018,2018-02-28,January 2022,Anticipated,2022-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa,Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa,Recruiting,NA,N/A,160,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,"After all primary analyses are complete, de-identified data will be available per request of outside individual.",2018-08-01T23:39:55Z,2018-08-01T23:39:55Z
NCT02571595,"ClinicalTrials.gov processed this data on August 01, 2018",2015-08-25,NA,NA,2017-09-19,2015-10-06,2015-10-08,Estimate,NA,NA,NA,NA,NA,NA,2017-09-19,2017-09-21,Actual,May 2015,NA,2015-05-31,September 2017,2017-09-30,May 2018,Anticipated,2018-05-31,May 2018,Anticipated,2018-05-31,NA,Interventional,NA,,A Sleep Program to Improve Sleep Quality in People With HIV,Efficacy Potential of an Internet-based Sleep Program to Improve Sleep Quality in People With HIV,Enrolling by invitation,NA,N/A,60,Anticipated,McGill University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,Fully anonymized individual data may be requested from the investigators.,2018-08-02T00:07:45Z,2018-08-02T00:07:45Z
NCT02571504,"ClinicalTrials.gov processed this data on August 01, 2018",2015-08-25,NA,NA,2017-09-19,2015-10-07,2015-10-08,Estimate,NA,NA,NA,NA,NA,NA,2017-09-19,2017-09-21,Actual,April 2015,Actual,2015-04-30,September 2017,2017-09-30,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,NA,Interventional,NA,,Cognitive Training for the Remediation of Functional Brain Health in HIV,Brain Imaging to Understand HIV-associated Neurocognitive Disorder and Predict Response to Cognitive Training,Completed,NA,N/A,81,Actual,McGill University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,Fully anonymized individual data may be requested from the investigators.,2018-08-02T00:07:47Z,2018-08-02T00:07:47Z
NCT02484183,"ClinicalTrials.gov processed this data on August 01, 2018",2015-06-23,NA,NA,2018-05-01,2015-06-25,2015-06-29,Estimate,NA,NA,NA,NA,NA,NA,2018-05-01,2018-05-03,Actual,"June 23, 2015",Actual,2015-06-23,May 2018,2018-05-31,"April 28, 2018",Actual,2018-04-28,"April 28, 2018",Actual,2018-04-28,NA,Interventional,IMPACT,,CPAP Improving Mortality for Pneumonia in African Children Trial,Effectiveness of Bubble Continuous Positive Airway Pressure (CPAP) in Reducing Childhood Pneumonia Mortality in Malawi,Terminated,NA,N/A,646,Actual,Johns Hopkins University,,2,NA,By Data Safety and Monitoring Board after second interim analysis and follow-up safety check.,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,,Yes,Will be available upon request to principle investigator.,2018-08-02T00:26:30Z,2018-08-02T00:26:30Z
NCT02473367,"ClinicalTrials.gov processed this data on August 01, 2018",2015-06-12,2016-07-19,NA,2017-02-20,2015-06-12,2015-06-16,Estimate,2016-07-19,2016-09-01,Estimate,NA,NA,NA,2017-02-20,2017-03-23,Actual,June 2015,NA,2015-06-30,February 2017,2017-02-28,October 2015,Actual,2015-10-31,August 2015,Actual,2015-08-31,NA,Interventional,NA,,The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824),A Study to Evaluate the Influence of Metal Cation-Containing Antacids on MK-0518 Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen,Completed,NA,Phase 1,20,Actual,Merck Sharp & Dohme Corp.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T00:28:56Z,2018-08-02T00:28:56Z
NCT02471326,"ClinicalTrials.gov processed this data on August 01, 2018",2015-06-12,2017-05-12,NA,2017-10-02,2015-06-12,2015-06-15,Estimate,2017-10-02,2017-10-31,Actual,NA,NA,NA,2017-10-02,2017-10-31,Actual,"July 13, 2015",NA,2015-07-13,October 2017,2017-10-31,"April 7, 2017",Actual,2017-04-07,"April 7, 2017",Actual,2017-04-07,NA,Interventional,NA,,VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption,"An Exploratory, Open-Label Study of VRC-HIVMAB060-00-AB (VRC01) in Subjects With Chronic HIV Infection Undergoing Analytical Treatment Interruption",Completed,NA,Phase 1,10,Actual,National Institutes of Health Clinical Center (CC),,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Yes,NIH Biomedical Translational Research Information System,2018-08-02T00:29:28Z,2018-08-02T00:29:28Z
NCT02348775,"ClinicalTrials.gov processed this data on August 01, 2018",2015-01-15,NA,NA,2018-01-24,2015-01-26,2015-01-28,Estimate,NA,NA,NA,NA,NA,NA,2018-01-24,2018-01-26,Actual,November 2014,NA,2014-11-30,January 2018,2018-01-31,December 2018,Anticipated,2018-12-31,December 2018,Anticipated,2018-12-31,NA,Interventional,NA,,Glutathione and Function in HIV Patients,Glutathione and Function in HIV Patients,"Active, not recruiting",NA,Phase 1,16,Actual,Baylor College of Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,Yes,Data from the study will be submitted for publication once analyses are completed,2018-08-02T00:56:21Z,2018-08-02T00:56:21Z
NCT02131233,"ClinicalTrials.gov processed this data on August 01, 2018",2014-05-02,2016-09-07,NA,2017-11-17,2014-05-02,2014-05-06,Estimate,2016-09-07,2016-10-31,Estimate,NA,NA,NA,2017-11-17,2017-12-14,Actual,"May 23, 2014",Actual,2014-05-23,November 2017,2017-11-30,"December 19, 2016",Actual,2016-12-19,"December 21, 2015",Actual,2015-12-21,NA,Interventional,onceMRK,All Treated Participants,"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADAâ„¢ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADAâ„¢, in Treatment-NaÃ¯ve HIV-1 Infected Subjects",Completed,NA,Phase 3,802,Actual,Merck Sharp & Dohme Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Yes,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php",2018-08-02T01:50:52Z,2018-08-02T01:50:52Z
NCT02063880,"ClinicalTrials.gov processed this data on August 01, 2018",2012-08-21,2017-05-01,NA,2018-04-11,2014-02-13,2014-02-17,Estimate,2017-05-02,2017-07-25,Actual,NA,NA,NA,2018-04-11,2018-05-14,Actual,March 2013,NA,2013-03-31,April 2018,2018-04-30,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,NA,Interventional,PUSH,,Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART),Urgent Versus Post-Stabilization ART in HIV-1 Infected Children With Severe Co-Infections,Completed,NA,N/A,183,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Yes,after primary and secondary outcomes are published,2018-08-02T02:10:24Z,2018-08-02T02:10:24Z
